PENTAX-MEDICAL
PENTAX Medical today announces the launch of a new high-definition (HD) pulmonology endoscopy system in the European, Middle Eastern & African (EMEA) markets. The new DEFINA system in Pulmonology combines a state-of-the art HD processor with i-scan imaging technology and two highly maneuverable HD bronchoscopes. This powerful combination serves to deliver outstanding HD image quality, which subsequently supports clinical outcomes across the complete range of diagnostic and therapeutic applications.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160701005101/en/
The HD DEFINA system delivers sharp and clear image quality, enabling rapid and highly detailed visualization for the improved evaluation of anatomical details of the bronchial mucosa. This in combination with i-scan technology facilitates the precise detection and demarcation of suspicious areas and assists in characterization of abnormalities to support therapeutic decisions.
Fully complying with increasing hygiene requirements, the new DEFINA system uses disposable accessories to reduce the risk of cross-contamination. It is also STERRAD® compatible, ensuring that it is clear of multidrug resistant and extreme drug resistant Mycobacterium. Further adding to patient safety, the new disposable suction valve is safely attached to the endoscope using a click mechanism that cannot be dislodged. This also delivers strong suction to efficiently remove secretion and control bleeding for precise sampling.
Used in conjunction with the EPK-3000 HD processor, the two HD bronchoscopes (EB15-J10 and EB19-J10) of the DEFINA system in Pulmonology are unmatched in their ergonomic design and ease of operation. The new-design lightweight control body of these J10 scopes has an ergonomically positioned suction valve, angulation levers and remote control buttons. Effortless maneuverability within the bronchus, with easy access even to the right upper lobe of the lung, is made possible due to the bronchoscopes’ 210˚ distal tip deflection and insertion tube flexibility.
Rainer Burkard, President EMEA of PENTAX Medical, commented: “Through our close relations with practising endoscopists worldwide, we have looked to develop a high-definition video endoscope system that delivers the optimum in visualization, providing crystal clarity. We have produced a system that also offers high standards of hygiene and ergonomics for the full range of diagnostic and therapeutic applications in the Pulmonology field. Our new DEFINA system in Pulmonology is engineered to support the delivery of best clinical outcomes and image quality.”
This new DEFINA system in Pulmonology will be commercially available from September 1st 2016 to all EMEA markets, except for Russia. In UK only the two HD bronchoscopes (EB15-J10 and EB19-J10) will be available.
About PENTAX Medical
PENTAX Medical is a division of HOYA Group. Its mission is to improve the standard of patient care and quality of healthcare delivery by providing the best endoscopic products and services with a focus on QUALITY, CLINICALLY RELEVANT INNOVATION, and SIMPLICITY. Through leading edge R&D and manufacturing, PENTAX Medical provides endoscopic imaging devices and solutions to the global medical community. Headquartered in Japan, PENTAX Medical has a worldwide focus and presence with R&D, regional sales, service, and in-country facilities around the globe. For more information, please visit: www.pentaxmedical.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20160701005101/en/
Contact:
PENTAX Europe GmbH
Sangeeta Gehlot-Vadher
EMEA PR Manager
T:
+44 (0)1753 792 733
F: +44 (0)1753 792 794
E: sangeeta.gehlot@pentaxmedical.com
W:
www.pentaxmedical.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Leading law firm launches industry first social justice fund10.6.2025 07:00:00 CEST | Press release
Initiative sets a new precedent that funds legal support for vulnerable individuals, while meeting the needs of business clients seeking socially responsible suppliers. Bindmans, an award-winning multidisciplinary law firm with a 50-year human rights and social justice record, has today set a new precedent in the legal industry by announcing the launch of its 10% Social Justice Fund (SJF). The fund will allocate 10% of business client fees to support individuals in gaining access to justice. It marks an industry first and serves the joint purpose of helping to improve the Environmental, Social, and Governance (ESG) scores of Bindmans’ corporate clients, enhancing their impact across the value chain through socially responsible legal services. Bindmans has a proud record in human rights and social justice, dedicated to providing legal services to those who need it most. The law firm was founded 50 years ago by one of the greatest Human Rights lawyers in the UK, Sir Geoffrey Bindman (KC)
FPT Proposes Public-Private Partnership Model to Develop Vietnam’s Digital Healthcare Ecosystem10.6.2025 06:17:00 CEST | Press release
Global IT services provider FPT and Pharma Group jointly hosted the Healthcare Innovation Forum - HIF 2025. The event served as a multi-stakeholder dialogue platform with a spotlight on breakthrough innovations in science, technology, and AI to accelerate healthcare advancements and drive digital transformation in public health services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609760138/en/ FPT Proposes Public-Private Partnership Model to Develop Vietnam’s Digital Healthcare Ecosystem The Forum was attended by Vietnam Deputy PM H.E. Le Thanh Long, key government officials, and international guests including U.S. Ambassador Marc Knapper, Swiss Ambassador Thomas Gass, former German Vice Chancellor Dr. Philipp Rösler, and representatives from Japan, Singapore, and Harvard Medical School. Vietnam Deputy PM H.E. Le Thanh Long stressed the urgent need to reform healthcare, outlining five strategies: accelerate digitaliza
China’s Center for Drug Evaluation Accepts Merck’s Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor10.6.2025 06:00:00 CEST | Press release
First global filing for potentially best-in-class TGCT treatment based on strong positive data from Phase 3 MANEUVER study Potential for pimicotinib to be first systemic TGCT therapy approved in China, following recent granting of Priority Review by CDEAdditional applications planned in the US and other markets around the world Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) officially accepted the company’s application for marketing authorization of pimicotinib as a Class 1 innovative drug for adult patients with tenosynovial giant cell tumors (TGCT) requiring systemic treatment. The submission follows the granting of Priority Review to pimicotinib by the CDE in May for the treatment of patients with TGCT who require systemic therapy, which is expected to expedite the review process. Pimicotinib, a potentially best-in-c
KuppingerCole Recognizes Regula as One of the Innovation Leaders in Identity Verification10.6.2025 03:00:00 CEST | Press release
Regula, a global developer of forensic devices and identity verification (IDV) solutions, has made its inaugural appearance in the KuppingerCole Leadership Compass for Identity Verification 2025. Mentioned in the Innovation Leaders category, the company is recognized for its 100% in-house R&D, forensic-grade technology, global document coverage, and advanced liveness detection capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609760424/en/ Regula’s innovative in-house technology powers fast, seamless identity checks—now recognized by KuppingerCole Analysts. Specializing in IDV and cybersecurity industry analysis, KuppingerCole forecasts that the global IDV market will grow from $18.4 billion in 2025 to $50.07 billion by 2030, driven by increasing identity fraud, compliance requirements, user expectations, and technological advancements. As identity verification rapidly shifts toward fully remote and automated e
IFF Appoints Virginia “Gina” Drosos to Board of Directors9.6.2025 23:46:00 CEST | Press release
IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients, health and biosciences—today announced the appointment of Gina Drosos to its board of directors, effective June 16. Drosos brings more than 30 years of executive leadership experience across the retail, consumer goods, beauty and health care industries. “We are very pleased to welcome Gina to the IFF board,” said Kevin O’Byrne, chair of the board. “Gina brings extensive relevant experience, deep consumer insights and a proven ability to drive innovation and lead with purpose, which aligns with our long-term strategy to deliver sustainable growth and value creation for all stakeholders.” Drosos most recently served as chief executive officer and a director of Signet Jewelers Ltd. (NYSE: SIG)—the world’s largest retailer of diamond jewelry—from August 2017 to November 2024. During her tenure, she led the company through a significant transformation, expanding its digital capabilities and enhancing customer experien
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom